Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

9 results about "Uremic toxins" patented technology

Uremic toxins. a name given to the many products of metabolism that accumulate in the body with renal failure, and in association with uremia, because of impaired renal degradation and/or excretory capacity.

Use of a compound for the preparation of a medicament for the removal of protein-bound uremic toxins from blood

The application belongs to the technical field of biological medicine, and more particularly relates to application of a compound in preparation of a medicine for removing protein-bound uremic toxins in blood. The compound has a structural general formula shown in formula (I): wherein R1 is an aromatic heterocycle with a carbon number of 6-50, a benzenepropyl aromatic heterocycle with a carbon number of 6-50, or an aromatic hydrocarbon with a carbon number of 6-50; and R2 is a flavonoid group with a carbon number of 13-50, a polyphenol group, or a terpenoid group. Experiments show that the compound has a competitive replacement removal effect significantly better than that of the currently best replacement medicine, shikonin acid (LA), when the compound is used to remove protein-bound uremic toxins (PBUTs) such as IS and PCS by using a competitive replacement method, and the advantage is more obvious at a low concentration.
Owner:BINZHOU MEDICAL COLLEGE

Double-layer hollow fiber membrane for hemodialysis and its manufacturing method

PendingJP2026503333AMembranesDialysisBlood componentMetabolic waste
The present invention provides a double-layer hollow fiber membrane for enclosing a hollow space through which blood flows and transporting uremic toxins and waste products from the blood to the outside, and a method for manufacturing the same. The double-layer hollow fiber membrane includes a first layer having first pores and a second layer having second pores. The first pores of the first layer and the second pores of the second layer are connected to each other, and the second pores are open pores connected to the outside. The double-layer hollow fiber membrane can remove uremic toxins with molecular sizes from blood while minimizing the loss of blood components and essential proteins due to the pores increasing in size from the first pores to the second pores.
Owner:INOSEP INC

Anti-uremic toxin antibodies and methods of use thereof

The present invention relates to antibodies or antigen-binding fragments thereof, specific for a uremic toxin(s), compositions comprising these antibodies or antigen-binding fragments, and methods of use thereof.
Owner:NEW YORK UNIV

Traditional Chinese medicine compound preparation for treating nephrotic syndrome and preparation method thereof

The invention discloses a traditional Chinese medicine compound preparation for treating nephrotic syndrome and a preparation method of the traditional Chinese medicine compound preparation, and belongs to the technical field of nephrotic syndrome treatment.The synbiotic microcapsule is prepared by compatibility of traditional Chinese medicines such as safflower, scutellaria baicalensis and perilla frutescens, and the synbiotic microcapsule is prepared by embedding traditional Chinese medicine extracts such as astragalus membranaceus and lily with lactobacillus acidophilus and bifidobacterium; and the wall material is prepared from mannose grafted meadowfoam seed extract, sodium alginate and fucoidin sulfate. The synbiotics microcapsule utilizes a Maillard reaction modified wall material to enhance gastric acid erosion resistance, realizes intestinal targeted colonization through mannose residues, protects probiotics, directionally releases traditional Chinese medicine active components, adjusts intestinal flora balance and inhibits uremia toxin generation. The traditional Chinese medicine components such as the safflower and the scutellaria baicalensis improve kidney blood circulation, relieve inflammatory response and regulate lipid metabolism by inhibiting an NF-kappa B channel, activating an AMPK channel and the like; the components such as the Chinese yam and the Chinese wolfberry can repair the permeability of glomerular basement membrane and improve the hypoproteinemia.
Owner:THE SECOND AFFILIATED HOSPITAL OF HUNAN UNIV OF TRADITIONAL CHINESE MEDICINE

System for removing uremic toxins in dialysis processes

A method of performing dialysis includes: recirculating a dialysis fluid from a patient or a dialyzer for at least two cycles, each cycle contacting the dialysis fluid first with a zirconium phosphate layer followed by at least one of a urease layer, a zirconium oxide layer, or a carbon layer; storing the recirculated dialysis fluid in a storage container; and transferring the dialysis fluid from the storage container to the patient or the dialyzer. In one example, the zirconium phosphate layer and the at least one of the urease layer, the zirconium oxide layer, or the carbon layer is provided by a sorbent cartridge.
Owner:VANTIVE US HEALTHCARE LLC +1

Activated carbon adsorbent

The present invention provides an activated carbon adsorbent for oral administration, wherein the activated carbon adsorbent is in the form of particles obtained by carbonization and subsequent activation of poly(styrene-co-divinylbenzene) particles, wherein the poly(styreneco-divinylbenzene) particles are macroporous and have a moisture content of from about 5 wt% to about 60 wt% relative to the total mass of the poly(styrene-co- divinylbenzene) particles. The present invention also provides an activated carbon adsorbent for oral administration, wherein the activated carbon adsorbent is in the form of particles, comprises micropores and mesopores, and has a total surface area of at least about 1000 m2 / g and a total pore volume of at least about 1 cm3 / g, wherein at least about 50% of the total pore volume is formed by the micropores, and at least about 20% of the total pore volume is formed by the mesopores. The present disclosure also provides a pharmaceutical composition comprising an activated carbon adsorbent of the present invention, and an in vitro method of removing one or more uremic toxins from a fluid using an activated carbon adsorbent of the present invention. As disclosed herein, the activated carbon adsorbents also find utility in the treatment of a renal disease or a liver disease.
Owner:AWAK TECH PTE LTD +1

Combination of microbial components for reducing uremic toxins in cardiovascular metabolism or neurodegenerative disorders

The present invention relates to compositions for reducing or avoiding uremic toxin accumulation in cardiovascular metabolism or neurodegenerative disorders, in particular compositions comprising probiotics, prebiotics (carbohydrates or fibres) and lipids.
Owner:SOCIETE DES PRODUITS NESTLE SA

Method for detecting protein binding uremic toxins and use thereof

ActiveCN116106444BComponent separationFluid phaseProtein bound uremic toxin
The application provides a method and application for detecting protein-bound uremic toxins, which comprises the following steps: mixing a blood sample and a protein precipitation extractant, centrifugally separating to obtain supernatant, mixing the supernatant and the protein precipitation extractant, centrifugally separating, filtering the treated supernatant to obtain a sample solution to be detected; preparing a standard solution of each sample to be detected, mixing the standard solutions of all the samples to be detected, and preparing a plurality of mixed standard solutions with different concentrations of the samples to be detected; performing high performance liquid chromatography on the mixed standard solutions to draw a standard curve between the concentration and the peak area of each sample to be detected, performing high performance liquid chromatography on the sample solution to be detected to obtain the determination peak area of each sample to be detected, and calculating the content of each sample to be detected according to the corresponding standard curve. The application solves the problems of low detection sensitivity and difficulty in accurate detection of the existing detection methods.
Owner:JAFRON BIOMEDICAL

Composition for preventing, ameliorating, or treating kidney and / or liver diseases via antiinflammation, antioxidation, antifibrosis, and uremic toxin excretion, comprising complex (neprobin) of ganoderma lucidum extract and robinia pseudoacacia flower extract as active ingredient

The present invention relates to a composition for preventing, ameliorating, or treating kidney and liver diseases, comprising a complex (NEPROBIN) of Ganoderma lucidum extract and Robinia pseudoacacia flower extract as an active ingredient. The complex provided from the present invention exhibits excellent effects in preventing kidney damage, maintaining kidney function, and regenerating kidney tissue by means of inhibition of NO production, reduction in cytokine (TNF-a) and Crp gene expression, increase in glutathione, reduction in ROS production, and increase in uremic toxin excretion, and exhibits excellent effects in preventing liver damage and improving liver function by means of inhibition of NO production, reduction in cytokine (IL6) and MCP1 and CXCL1 gene expression, increase in glutathione, suppression of expression of fibrosis markers (ACTA2, Vim, COL3A1) of hepatic stellate cells, restoration of GSH in liver tissue, increase in antioxidant enzyme activity, and suppression of expression of antiinflammatory- and antifibrotic-related genes and proteins, and thus, the complex is applicable as a pharmaceutical composition for preventing or treating kidney and / or liver diseases, and as a health functional food and food composition for preventing or ameliorating liver diseases.
Owner:HLSCIENCE CO LTD